Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 400 of 2051 entries
View as:

A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00777608 Org: User:
Start: 12/31/08 End: 04/30/10 Due: 04/30/11

A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)

Phase: N/A Priority: Normal
NCT ID: NCT01728584 Org: User:
Start: 11/28/12 End: 04/29/14 Due: 04/29/15

Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00048594 Org: User:
Start: 01/03/02 End: 12/22/03 Due: 12/22/04

Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)

Phase: N/A Priority: Normal
NCT ID: NCT00243230 Org: User:
Start: 09/19/05 End: 03/17/11 Due: 03/17/12

Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019)

Phase: N/A Priority: Normal
NCT ID: NCT05818124 Org: User:
Start: 08/21/23 End: 06/28/24 Due: 06/28/25

Hepatitis B Challenge Dose in Adults (V232-059-10)

Phase: N/A Priority: Normal
NCT ID: NCT01251276 Org: User:
Start: 11/30/10 End: 04/12/11 Due: 04/12/12

Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00365716 Org: User:
Start: 05/31/00 End: 09/30/09 Due: 09/30/10

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00093080 Org: User:
Start: 10/31/04 End: 11/30/08 Due: 11/30/09

A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00782418 Org: User:
Start: 09/30/08 End: 03/31/09 Due: 03/31/10

Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

Phase: N/A Priority: Normal
NCT ID: NCT01425190 Org: User:
Start: 01/04/12 End: 03/20/13 Due: 03/20/14

A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)

Phase: N/A Priority: Normal
NCT ID: NCT06692647 Org: User:
Start: 02/09/24 End: 04/11/24 Due: 04/11/25

A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)

Phase: N/A Priority: Normal
NCT ID: NCT06691906 Org: User:
Start: 03/18/24 End: 05/01/24 Due: 05/01/25

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Phase: N/A Priority: Normal
NCT ID: NCT03829332 Org: User:
Start: 03/13/19 End: 04/24/24 Due: 04/24/25

A Study to Diagnose Lung Cancer by Sputum Cytology (01-312)

Phase: N/A Priority: Normal
NCT ID: NCT00210080 Org: User:
Start: 04/30/01 End: 12/31/03 Due: 12/31/04

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Phase: N/A Priority: Normal
NCT ID: NCT02116660 Org: User:
Start: 09/03/14 End: 07/10/17 Due: 07/10/18

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

Phase: N/A Priority: Normal
NCT ID: NCT03867084 Org: User:
Start: 05/28/19 End: 08/31/29 Due: 08/31/30

A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)

Phase: N/A Priority: Normal
NCT ID: NCT00322231 Org: User:
Start: 05/31/06 End: 07/31/07 Due: 07/31/08

A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

Phase: N/A Priority: Normal
NCT ID: NCT01314872 Org: User:
Start: 03/31/11 End: 10/10/13 Due: 10/10/14

Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)

Phase: N/A Priority: Normal
NCT ID: NCT00934466 Org: User:
Start: 07/31/09 End: 12/31/09 Due: 12/31/10

Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)

Phase: N/A Priority: Normal
NCT ID: NCT00704964 Org: User:
Start: 05/31/05 End: 10/31/09 Due: 10/31/10

Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

Phase: N/A Priority: Normal
NCT ID: NCT00684515 Org: User:
Start: 09/21/06 End: 11/08/07 Due: 11/08/08

SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)

Phase: N/A Priority: Normal
NCT ID: NCT00783393 Org: User:
Start: 05/27/03 End: 06/17/05 Due: 06/17/06

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

Phase: N/A Priority: Normal
NCT ID: NCT03776136 Org: User:
Start: 01/30/19 End: 10/11/23 Due: 10/11/24

A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet

Phase: N/A Priority: Normal
NCT ID: NCT00566267 Org: User:
Start: 04/30/06 End: 11/30/07 Due: 11/30/08

Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)

Phase: N/A Priority: Normal
NCT ID: NCT01907724 Org: User:
Start: 05/31/13 End: 08/31/13 Due: 08/31/14